T‐type calcium channels as therapeutic targets in essential tremor and Parkinson's disease

Neuronal action potential firing patterns are key components of healthy brain function.

Importantly, restoring dysregulated neuronal firing patterns has the potential to be a promising strategy in the development of novel therapeutics for disorders of the central nervous system.

Here, we review the pathophysiology of essential tremor and Parkinson's disease, the two most common movement disorders, with a focus on mechanisms underlying the genesis of abnormal firing patterns in the implicated neural circuits.

Aberrant burst firing of neurons in the cerebello‐thalamo‐cortical and basal ganglia‐thalamo‐cortical circuits contribute to the clinical symptoms of essential tremor and Parkinson's disease, respectively, and T‐type calcium channels play a key role in regulating this activity in both the disorders.

Accordingly, modulating T‐type calcium channel activity has received attention as a potentially promising therapeutic approach to normalize abnormal burst firing in these diseases.

In this review, we explore the evidence supporting the theory that T‐type calcium channel blockers can ameliorate the pathophysiologic mechanisms underlying essential tremor and Parkinson's disease, furthering the case for clinical investigation of these compounds.

We conclude with key considerations for future investigational efforts, providing a critical framework for the development of much needed agents capable of targeting the dysfunctional circuitry underlying movement disorders such as essential tremor, Parkinson's disease, and beyond.